Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer: a Multicentre, Open-label, Randomised Pragmatic Clinical Trial

NCT06052332 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT06052332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06052332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer: a Multicentre, Open-label, Randomised Pragmatic Clinical Trial
Lead sponsor
Jules Bordet Institute
Phase
Not applicable
Overall status
Recruiting
Start date
February 7, 2024
Completion date
December 31, 2033
Enrollment
230 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer, older people